Anti-COVID 19 hyperacute serum in the treatment of viral disease

  • Funded by Ministry for Innovation and Technology (Hungary)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    Ministry for Innovation and Technology (Hungary)
  • Principal Investigator

    N/A

  • Research Location

    Hungary
  • Lead Research Institution

    OrthoSera Ltd.
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The patented hyperacute serum technology of OrthoSera Ltd. may have an additional therapeutic effect in addition to antiviral antibodies: according to their studies, it can also reduce the excessive cytokine response. Hyperacute serum can be produced from the donors' blood. Extensive cooperation is being established in the project, the Institute of Modernization of the Hungarian Armed Forces, the virology working group of the University of Pécs and the Institute of Translational Medicine of Semmelweis University have joined, as well as several specialists and companies.